A protein identified by researchers at UT Southwestern Medical Center may drive resistance to immune checkpoint inhibitors, a ...

The global checkpoint inhibitor refractory cancer market is experiencing significant growth, with an expected valuation of USD 38.69 billion in 2023. This expansion is fueled by the rising health ...

An evaluation of nearly 19,000 patients with metastatic colorectal cancer supported clinical trial data that immunotherapy ...

OmRx Oncology, or "OmRx," a clinical-stage biopharmaceutical venture dedicated to expanding access to cancer immunotherapy worldwide, today announced the initiation of a Phase 2 clinical trial of its ...

Immunotherapy uses the power of your immune system to fight your cancer. One type of immunotherapy is called an immune checkpoint inhibitor. Your immune system has built-in checkpoints that help it ...

OmRx Oncology begins phase 2 trial of oral PD-L1 inhibitor OX-4224 in patients with non-small cell lung cancer: San Diego Saturday, May 10, 2025, 12:00 Hrs [IST] OmRx Oncology, or ...

As lead candidate mipletamig continues to outperform efficacy and safety benchmarks in AML trials, APVO711 exemplifies emerging innovation from Aptevo's proprietary ADAPTIR® platform In preclinical ...

Seniors with cancer respond just as well as younger patients to immune checkpoint inhibitors immunotherapy treatment.

A "groundbreaking" cancer treatment trial by Memorial Sloan Kettering shows immunotherapy alone can eliminate some tumors, ...

An investigational viral immunotherapy extended survival compared with standard care for patients with advanced non-small cell lung cancer who had inadequate response to immune checkpoint inhibitor ...

One of the best ways to defeat cancer is by rousing the immune system to attack it. Experts have thought that immune cells had to be inside of tumors for one type of immunotherapy, known as ...